Oscar Health Warns CMS Churn to Double, Stock Drops 13% Despite Q2 Beat
OSCR has more than doubled off its 52-week low of $10.69.
Summary
Oscar Health posted a strong Q2 beat with $4.88B revenue and $1.10 EPS, but shares fell 13% after the CFO warned that CMS-driven membership churn will be roughly double the prior 1-2% estimate. The churn is tied to eligibility verification and program integrity reviews, and management stressed it is a timing issue already reflected in the reaffirmed full-year revenue guidance of $18.7B-$19.0B. The medical loss ratio improved to 79.2% from 91.1% a year ago, and the company narrowed its full-year MLR forecast to 81.5%-82.5%. The selloff reflects investor concern that higher churn could pressure membership growth and future earnings, despite record first-half profitability. This follows the earlier Q2 release and raised outlook, but the churn warning and sharp price drop are new developments.
At the time of this announcement, OSCR was trading at $26.76 on NYSE in the Finance sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $10.69 to $33.10. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.